Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention

References

• Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359(9):938-49
   PubMed Web of Science ®Google Scholar
• Horne M. Overview of hemostasis and thrombosis; current status of antithrombotic therapies. Thromb Res 2005;117(1-2):15-17. discussion 39-42
   PubMedGoogle Scholar
• Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992;267(16):11300-6
   PubMedGoogle Scholar
• Collet JP, Montalescot G. Platelet function testing and implications for clinical practice. J Cardiovasc Pharmacol Ther 2009;14(3):157-69
   PubMedGoogle Scholar
• Cohen M. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the. 2007 AHA/ACC/SCAI guidelines and beyond. Catheter Cardiovasc Interv 2009;74(4):579-97
   PubMedGoogle Scholar
• Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50(7):e1-e157
   PubMedGoogle Scholar
• Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61(23):e179-347
   PubMed Web of Science ®Google Scholar
• Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32(23):2999-3054
   PubMed Web of Science ®Google Scholar
• Sakhuja R, Yeh RW, Bhatt DL. Antiplatelet agents in acute coronary syndromes. Curr Probl Cardiol 2010;35(3):123-70
   PubMed Web of Science ®Google Scholar
• Weintraub WS, Mandel L, Weiss SA. Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations. Pharmacoeconomics 2013;31(11):959-70
   PubMedGoogle Scholar
• Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013;369(11):999-1010
   PubMed Web of Science ®Google Scholar
• Bellemain-Appaix A, O’Connor SA, Silvain J, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA 2012;308(23):2507-16
   PubMed Web of Science ®Google Scholar
• Szuk T, Gyongyosi M, Homorodi N, et al. Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. Am Heart J 2007;153(2):289-95
   PubMedGoogle Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360(4):354-62
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360(4):363-75
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373(9660):309-17
   PubMed Web of Science ®Google Scholar
• Williams CD, Cherala G, Serebruany V. Application of platelet function testing to the bedside. Thromb Haemost 2010;103(1):29-33
   PubMedGoogle Scholar
• Braunwald E, Angiolillo D, Bates E, et al. Assessing the current role of platelet function testing. Clin Cardiol 2008;31(3 Suppl 1):I10-16
   Google Scholar
• Mueller T, Dieplinger B, Poelz W, Haltmayer M. Utility of the PFA-100 instrument and the novel multiplate analyzer for the assessment of aspirin and clopidogrel effects on platelet function in patients with cardiovascular disease. Clin Appl Thromb Hemost 2009;15(6):652-9
   PubMed Web of Science ®Google Scholar
• Kaikita K, Ono T, Iwashita S, et al. Impact of CYP2C19 polymorphism on platelet function tests and coagulation and inflammatory biomarkers in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb 2014;21(1):64-76
   PubMedGoogle Scholar
• Yu XY, Chen JY, Zheng ZW, et al. Plasma miR-126 as a potential marker predicting major adverse cardiac events in dual antiplatelet-treated patients after percutaneous coronary intervention. EuroIntervention 2013;9(5):546-54
   PubMed Web of Science ®Google Scholar
• Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367(22):2100-9
   PubMed Web of Science ®Google Scholar
• Aradi D, Storey RF, Komocsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014;35(4):209-15
   PubMed Web of Science ®Google Scholar
• Sinhal AR, Aylward PE. New antiplatelet agents and the role of platelet function testing in acute coronary syndromes. Clin Ther 2013;35(8):1064-8
   PubMedGoogle Scholar
• Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56(12):919-33
   PubMed Web of Science ®Google Scholar
• Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62(24):2261-73
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303(8):754-62
   PubMed Web of Science ®Google Scholar
• Berger JS, Stebbins A, Granger CB, et al. Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation 2008;117(2):192-9
   PubMedGoogle Scholar
• Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):234S-64S
   PubMed Web of Science ®Google Scholar
• Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309(7):396-403
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86
   PubMed Web of Science ®Google Scholar
• Simon DI, Jozic J. Drug-eluting stents and antiplatelet resistance. Am J Cardiol 2008;102(9 Suppl):29J-37J
   Google Scholar
• Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295(2):180-9
   PubMed Web of Science ®Google Scholar
• Jefferson BK, Foster JH, McCarthy JJ, et al. Aspirin resistance and a single gene. Am J Cardiol 2005;95(6):805-8
   PubMed Web of Science ®Google Scholar
• Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007;297(18):2018-24
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58(24):e44-122
   PubMed Web of Science ®Google Scholar
• Miyata S, Miyata T, Kada A, Nagatsuka K. [Aspirin resistance]. Brain Nerve 2008;60(11):1357-64
   PubMedGoogle Scholar
• Reny JL, Bonvini RF, Barazer I, et al. [The concept of aspirin "resistance": mechanisms and clinical relevance]. Rev Med Interne 2009;30(12):1020-9
   PubMedGoogle Scholar
• Frelinger AL 3rd, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006;113(25):2888-96
   PubMed Web of Science ®Google Scholar
• Feng CH, White AA, Stevenson DD. Characterization of aspirin allergies in patients with coronary artery disease. Ann Allergy Asthma Immunol 2013;110(2):92-5
   PubMedGoogle Scholar
• Badar A, Scaife J, Yan AT, et al. Provision of gastroprotective medication and bleeding risk following acute coronary syndrome. J Invasive Cardiol 2013;25(8):397-401
   PubMedGoogle Scholar
• Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000;21(24):2033-41
   PubMed Web of Science ®Google Scholar
• Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005;31(2):174-83
   PubMed Web of Science ®Google Scholar
• Jarvis B, Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2000;60(2):347-77
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102(6):624-9
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39(1):9-14
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494-502
   PubMed Web of Science ®Google Scholar
• Reinhart KM, White CM, Baker WL. Prasugrel: a critical comparison with clopidogrel. Pharmacotherapy 2009;29(12):1441-51
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006;48(7):1339-45
   PubMed Web of Science ®Google Scholar
• Patti G, Pasceri V, Mangiacapra F, et al. Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELOAD-ACS] trial). Am J Cardiol 2013;112(2):162-8
   PubMedGoogle Scholar
• Sharma RK, Reddy HK, Singh VN, et al. Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag 2009;5:965-72
   PubMedGoogle Scholar
• Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109(25):3171-5
   PubMed Web of Science ®Google Scholar
• Roberts DI, Nawarskas JJ. Treatment Options for Patients With Poor Clopidogrel Response. Cardiol Rev 2013;21(6):309-17
   PubMedGoogle Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357(20):2001-15
   PubMed Web of Science ®Google Scholar
• Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153(1):66. e69-16
   PubMed Web of Science ®Google Scholar
• Mogabgab O, Wiviott SD, Cannon CP, et al. Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 Trial. J Cardiovasc Pharmacol Ther 2013;18(6):555-9
   PubMedGoogle Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008;371(9621):1353-63
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118(16):1626-36
   PubMed Web of Science ®Google Scholar
• Xanthopoulou I, Stavrou EF, Kassimis G, et al. Resistance to high-maintenance dose of prasugrel treated by ticagrelor: a case report. Platelets 2013;24(3):239-41
   PubMed Web of Science ®Google Scholar
• Cheema AN, Mohammad A, Hong T, et al. Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation. J Am Coll Cardiol 2011;58(14):1445-54
   PubMedGoogle Scholar
• von Tiehl KF, Price MJ, Valencia R, et al. Clopidogrel desensitization after drug-eluting stent placement. J Am Coll Cardiol 2007;50(21):2039-43
   PubMedGoogle Scholar
• Mutnick JL. Desensitization to prasugrel: cardiology’s increased need for allergy consultation. Ann Allergy Asthma Immunol 2012;108(2):124-5
   PubMed Web of Science ®Google Scholar
• Lokhandwala J, Best PJ, Henry Y, Berger PB. Allergic reactions to clopidogrel and cross-reactivity to other agents. Curr Allergy Asthma Rep 2011;11(1):52-7
   PubMedGoogle Scholar
• Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27(9):1038-47
   PubMed Web of Science ®Google Scholar
• Fabre JE, Gurney ME. Limitations of current therapies to prevent thrombosis: a need for novel strategies. Mol Biosyst 2010;6(2):305-15
   PubMedGoogle Scholar
• Alexopoulos D, Goudevenos JA, Xanthopoulou I, et al. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). Int J Cardiol 2013;168(6):5329-35
   PubMedGoogle Scholar
• Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50(19):1852-6
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361(11):1045-57
   PubMed Web of Science ®Google Scholar
• Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375(9711):283-93
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006;151(3):689. e681 689. e610
   PubMedGoogle Scholar
• Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361(24):2330-41
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012;307(3):265-74
   PubMed Web of Science ®Google Scholar
• Hantgan RR, Hindriks G, Taylor RG, et al. Glycoprotein Ib, von Willebrand factor, and glycoprotein IIb:IIIa are all involved in platelet adhesion to fibrin in flowing whole blood. Blood 1990;76(2):345-53
   PubMedGoogle Scholar
• Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332(23):1553-9
   PubMedGoogle Scholar
• Proimos G. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors. J Thromb Thrombolysis 2001;11(2):99-110
   PubMedGoogle Scholar
• Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001;103(2):201-6
   PubMed Web of Science ®Google Scholar
• Cayla G, Morange PE, Chambost H, Schved JF. Management of cardiovascular disease in haemophilia. Thromb Res 2013;132(1):8-14
   PubMedGoogle Scholar
• Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000;284(12):1549-58
   PubMed Web of Science ®Google Scholar
• Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330(14):956-61
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Lincoff AM, Miller DP, et al. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation 1998;97(9):857-64
   PubMedGoogle Scholar
• Tcheng JE, Kereiakes DJ, Braden GA, et al. Readministration of abciximab: interim report of the ReoPro readministration registry. Am Heart J 1999;138(1 Pt 2):S33-8
   Google Scholar
• Nowakowski K, Rogers J, Nelson G, Gunalingam B. Abciximab-induced thrombocytopenia: management of bleeding in the setting of recent coronary stents. J Interv Cardiol 2008;21(1):100-5
   PubMedGoogle Scholar
• Mascelli MA, Lance ET, Damaraju L, et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97(17):1680-8
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ. Prophylactic platelet transfusion in abciximab-treated patients requiring emergency coronary bypass surgery. Am J Cardiol 1998;81(3):373
   PubMedGoogle Scholar
• Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357(9272):1915-24
   PubMed Web of Science ®Google Scholar
• Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76(17):1222-7
   PubMed Web of Science ®Google Scholar
• Sperling RT, Pinto DS, Ho KK, Carrozza JP Jr. Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis. Catheter Cardiovasc Interv 2003;59(4):459-62
   PubMedGoogle Scholar
• Bougie DW, Rasmussen M, Zhu J, Aster RH. Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of alphaIIb/beta3 integrin. Blood 2012;119(26):6317-25
   PubMed Web of Science ®Google Scholar
• Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002;100(6):2071-6
   PubMed Web of Science ®Google Scholar
• ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356(9247):2037-44
   PubMedGoogle Scholar
• A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998;338(21):1498-505
   PubMed Web of Science ®Google Scholar
• Hermanides RS, Ottervanger JP, ten Berg JM, et al. Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score. J Invasive Cardiol 2012;24(3):84-9
   PubMedGoogle Scholar
• Van’t Hof AW, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008;372(9638):537-46
   PubMed Web of Science ®Google Scholar
• Batchelor WB, Tolleson TR, Huang Y, et al. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison of measurements of platelet aggregation with aggrastat, reopro, and eptifibatide. Circulation 2002;106(12):1470-1476
   PubMed Web of Science ®Google Scholar
• Leonardi S, Tricoci P, White HD, et al. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA.CER) trial. Eur Heart J 2013;34(23):1723-31
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet 2012;380(9850):1317-24
   PubMed Web of Science ®Google Scholar
• Singh J, Zeller W, Zhou N, et al. Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding. ACS Chem Biol 2009;4(2):115-26
   PubMed Web of Science ®Google Scholar
• Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007;100(9):1261-75
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005;95(10):1218-22
   PubMed Web of Science ®Google Scholar
• Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366(1):20-33
   PubMed Web of Science ®Google Scholar
• Sakurai R, Koo BK, Kaneda H, et al. Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. Int J Cardiol 2013;167(5):2250-8
   PubMedGoogle Scholar
• Chen Y, Zhang Y, Tang Y, et al. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. Curr Med Res Opin 2014;30(1):37-49
   PubMed Web of Science ®Google Scholar
• Morici N, Cantoni S, Savonitto S. Antiplatelet therapy for patients with stable ischemic heart disease and baseline thrombocytopenia: ask the hematologist. Platelets 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Patel AJ, Liu HH, Lager RA, et al. Successful percutaneous coronary intervention in a patient with combined deficiency of FV and FVIII due to novel compound heterozygous mutations in LMAN1. Haemophilia 2013;19(4):607-10
   PubMedGoogle Scholar
• Stabile E, Nammas W, Salemme L, et al. The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J Am Coll Cardiol 2008;52(16):1293-8
   PubMedGoogle Scholar
• Fox KA, Steg PG, Eagle KA, et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007;297(17):1892-900
   PubMed Web of Science ®Google Scholar